Clinical Characteristics, Treatment and Prognosis of 47 Non-small Cell Lung Cancer with Neuroendocrine Differentiation Patients.
10.3779/j.issn.1009-3419.2019.08.05
- Author:
Xiaoyan LI
1
;
Huayan XU
2
;
Xun KANG
1
;
Jing ZHAO
2
;
Yi LIN
1
;
Shasha WANG
2
;
Xiaoqing LIU
2
Author Information
1. Department of Oncologic Comprehensive Therapy, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China.
2. Department of Lung Cancer, The Fifth Medical Center, General Hospital of People's Liberation Army, Beijing 100071, China.
- Publication Type:Journal Article
- Keywords:
Driver gene;
Lung neoplasms;
Neuroendocrine differentiation;
Prognosis
- From:
Chinese Journal of Lung Cancer
2019;22(8):507-511
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND:Non-small cell lung cancer (NSCLC) with neuroendocrine differentiation (NED) was a new pathologic type and uncommon in clinics. The aim of this study is to observe the relationship between clinical pathologic characteristics, imagination, biological behavior and prognosis in NSCLC-NED.
METHODS:The clinical data of 47 patients with NSCLC-NED admitted from January 2009 to November 2017 in the Fifth Medical Center of General Hospital of People's Liberation Army were collected. The demographic data and imaging characteristics were summarized. Pathological features, treatment and prognosis, analysis of the correlation between different factors and prognosis.
RESULTS:Of the 47 patients with NSCLC-NED, the median age was 61 years (45 years-78 years), 38 males and 9 females; 37 were poorly differentiated cancer with NED, and 10 were middle differentiated cancer with NED; 2 cases of driving gene positive (1 case of EGFR sensitive mutation, 1 case of ALK fusion), objective response rate (ORR) of first-line chemotherapy was 34.5%, and median progression-free survival (PFS) was 4 months; the median overall survival (OS) was 11 months, and only 2 cases (4.2%, 2/47) of OS were over 2 years.
CONCLUSIONS:NSCLC-NED is different from simple NSCLC or pulmonary neuroendocrine tumors. Males, ≤70 years old, severely smoking, and patients with lower tumor differentiation often have NED, and most of them are stage IV. This type of patient-driven gene positive proportion is lower than the general adenocarcinoma population, less sensitive to chemotherapy, and the overall survival is shorter, indicating a poor prognosis.
